Abbreviations, acronyms & symbols | ||||
---|---|---|---|---|
CABG | = Coronary artery bypass grafting | LAD | = Left anterior descending artery | |
CAD | = Coronary artery disease | LIMA | = Left internal mammary artery | |
CK-MB | = Creatine kinase MB | LMCA | = Left main coronary artery | |
CPB | = Cardiopulmonary bypass | MACCE | = Major adverse cardiovascular and cerebrovascular events |
|
CTA | = Computed tomography angiography | MI | = Myocardial infarction | |
CT | = Computed tomography | PCI | = Percutaneous coronary intervention | |
GSV | = Great saphenous vein | SVG | = Saphenous vein graft | |
HTK | = Histidine-tryptophan-ketoglutarate | TTFM | = Transit-time flow measurement | |
ICU | = Intensive care unit |
Reconstruction (n=32) | Standard (n=128) |
P-value | |
---|---|---|---|
Age (years) | 62.1±9.4 | 63.7±11.4 | 0.83 |
Gender, male, n (%) | 23 (71.9) | 107 (83.6) | 0.21 |
BMI (kg/m2) | 23.5±3.8 | 23.2±3.6 | 0.66 |
Smoking history, n (%) | 19 (59.4) | 73 (57.0) | 0.84 |
MI, n (%) | 9 (28.1) | 36 (28.1) | 0.92 |
Left ventricular ejection fraction (%) | 59.5±11.5 | 62.1±9.9 | 0.48 |
Number of diseased arteries, n (%) | |||
2 | 3 (9.4) | 13 (10.2) | |
3 | 29 (90.6) | 115 (89.8) | |
Diabetes, n (%) | 10 (31.3) | 48 (37.5) | 0.76 |
Hypertension, n (%) | 18 (26.3) | 75 (58.6) | 0.68 |
Peripheral vascular diseases, n (%) | 3 (9.4) | 5 (3.9) | 0.32 |
Cerebrovascular diseases, n (%) | 4 (12.5) | 15 (11.7) | 0.91 |
Chronic renal insufficiency, n (%) | 1 (3.1) | 3 (3.9) | >0.99 |
Reconstruction (n=32) | Standard (n=128) |
P-value | |
---|---|---|---|
Number of bypassed arteries, n (%) | 0.01 | ||
2 | 10 (31.3) | 14 (10.9) | |
3 | 14 (43.8) | 76 (59.4) | |
4 | 8 (25.0) | 38 (29.7) | |
Blood flow in LAD (ml/min) | 35.3±8.7 | 28±13.6 | 0.51 |
Blood flow in SVG (ml/min) | 39.1±18.6 | 36.1±14.8 | 0.96 |
Cardiopulmonary bypass time (min) | 116.5±21.3 | 97.2±29.6 | 0.04 |
Aortic cross-clamping time (min) | 95.3±21.5 | 66.9±20.7 | <0.01 |
Ventilator support time (h) | 18.8±9.1 | 18.7±11.3 | 0.74 |
ICU length of stay (d) | 3.1±1.5 | 3.3±1.3 | 0.09 |
Postoperative atrial fibrillation, n (%) | 3 (9.4) | 15 (11.7) | 0.68 |
Postoperative MI, n (%) | 0 | 2 (1.6) | 0.75 |
Postoperative renal insufficiency, n (%) | 1 (3.1) | 2 (1.6) | 0.79 |
Postoperative stroke, n (%) | 0 | 2 (1.6) | 0.88 |
Ventricular arrhythmias, n (%) | 0 | 1 (0.8) | 0.93 |
Reconstruction (n=32) | Standard (n=128) |
P-value | |
---|---|---|---|
Troponin T (ng/ml) | |||
1st postoperative day | 0.3±0.1 | 0.3±0.2 | 0.58 |
2nd postoperative day | 0.3±0.2 | 0.3±0.3 | 0.89 |
3rd postoperative day | 0.2±0.1 | 0.3±0.1 | 0.67 |
CK-MB (ng/ml) | |||
1st postoperative day | 12.0±5.4 | 11.3±6.4 | 0.59 |
2nd postoperative day | 7.0±0.8 | 7.7±0.5 | 0.73 |
3rd postoperative day | 2.4±0.8 | 3.3±1.7 | 0.55 |
Reconstruction (n=32) | Standard (n=125) |
P-value | |
---|---|---|---|
Mortality rate, n (%) | 1 (3.1) | 2 (1.6) | 0.87 |
Incidence of MACCE, n (%) | 2 (6.3) | 7 (5.6) | 0.77 |
LIMA graft patency rate, n (%) | 32 (100.0) | 119 (99.2) | 0.48 |
Vein graft patency rate, n (%) | 31 (96.9)* * A patient can undergo bypass with multiple venous bridges; 32 patients had a total of 62 venous bridges; one failed; the patency rate was 61/62 (98.4%). | 118 (98.3)** ** A patient can undergo bypass with multiple venous bridges; 120 patients had a total of 264 venous bridges; three failed; the patency rate was 261/264 (98.7%). | 0.56 |
Authors' roles & responsibilities | |
---|---|
DL | Substantial contributions to the conception or design of the work; or the acquisition, analysis or interpretation of data for the work; drafting the work or revising it critically for important intellectual content; final approval of the version to be published |
PG | Substantial contributions to the conception or design of the work; or the acquisition, analysis or interpretation of data for the work; final approval of the version to be published |
LC | Substantial contributions to the conception or design of the work; or the acquisition, analysis or interpretation of data for the work; final approval of the version to be published |
YW | Substantial contributions to the conception or design of the work; or the acquisition, analysis or interpretation of data for the work; final approval of the version to be published |
GW | Substantial contributions to the conception or design of the work; or the acquisition, analysis or interpretation of data for the work; final approval of the version to be published |
CX | Substantial contributions to the conception or design of the work; or the acquisition, analysis or interpretation of data for the work; drafting the work or revising it critically for important intellectual content; final approval of the version to be published |